Drug profile

The FDA adverse-event record for Florfenicol, Terbinafine, Mometasone Furoate

58 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Florfenicol, Terbinafine, Mometasone Furoate. See the species affected, top reactions, and outcomes below.

58
adverse-event reports
20.7%
death-coded share
Dog
most-reported species
12
Vomiting - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
58
Total Reports
12
Deaths Reported
20.7%
Death Rate

Active Ingredients

Florfenicol, Terbinafine, Mometasone Furoate

Administration Routes

Auricular (Otic)UnknownTopicalOther

Species Affected

Dog 53
Cat 5

Most Affected Breeds

Retriever - Labrador 9
Retriever - Golden 7
Terrier - Yorkshire 3
Terrier (unspecified) 3
Spaniel - Springer English 3
American Pit Bull Terrier 2
Dog (unknown) 2
Domestic Shorthair 2
Crossbred Canine/dog 2
Terrier - Bull - American Pit 2

Most Reported Reactions

Vomiting 12
Lethargy (see also Central nervous system depression in Neurological) 10
Diarrhoea 9
Decreased appetite 7
Not eating 7
Death 7
Lethargy (see also Central nervous system depression in 'Neurological') 5
Other abnormal test result NOS 5
Polydipsia 5
Death by euthanasia 5
Proteinuria 5
Pruritus 5

Outcome Breakdown

Ongoing
28 (48.3%)
Outcome Unknown
9 (15.5%)
Recovered/Normal
9 (15.5%)
Died
7 (12.1%)
Euthanized
5 (8.6%)

Florfenicol, Terbinafine, Mometasone Furoate Adverse Event Insights

58 reports name Florfenicol, Terbinafine, Mometasone Furoate; 12 recorded a death outcome (20.7% of reported events, not a population-level mortality rate). Active ingredient: Florfenicol, Terbinafine, Mometasone Furoate. Administration routes: Auricular (Otic), Unknown, Topical, Other.

By species: Dog (53 reports), Cat (5 reports). By breed: Retriever - Labrador (9), Retriever - Golden (7), Terrier - Yorkshire (3).

Leading clinical signs: Vomiting (12), Lethargy (see also Central nervous system depression in Neurological) (10), Diarrhoea (9), Decreased appetite (7). Outcome, 58 coded reports: Ongoing leads at 48.3%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.